Nivolumab is a type of immunotherapy drug known as a checkpoint inhibitor. It is a monoclonal antibody that targets the PD-1 (programmed death-1) receptor on the surface of T cells, which are part of the immune system. By blocking PD-1, nivolumab helps to activate T cells to attack cancer cells.
